World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 3 October 2023
Main ID:  NCT02039401
Date of registration: 15/01/2014
Prospective Registration: Yes
Primary sponsor: Helixmith Co., Ltd.
Public title: Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
Scientific title: A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis
Date of first enrolment: March 2014
Target sample size: 18
Recruitment status: Completed
URL:  https://clinicaltrials.gov/ct2/show/NCT02039401
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 1/Phase 2
Countries of recruitment
United States
Contacts
Name:     John A Kessler, MD
Address: 
Telephone:
Email:
Affiliation:  Northwestern University Stem Cell Institute
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age = 21 years, but < or = 75 years

- Subjects diagnosed with:

- clinically definite ALS,

- clinically probable ALS, or

- clinically probable-laboratory supported ALS as specified in the revised El
Escorial / Airlie House diagnostic criteria

- Onset of ALS < 2 years at Screening

- Forced Vital Capacity (FVC) = 60% of predicted

- Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) = 30

- Not taking riluzole, or on a stable dose for at least thirty days prior to Screening
(defined as no noted toxicities)

- Able and willing to give informed consent

- If female of childbearing potential, negative urine pregnancy test at Screening and
using acceptable method of birth control during the study.

Exclusion Criteria:

- Neurological symptom(s) due to vitamin B12 deficiency

- Requires tracheotomy ventilation or noninvasive ventilation > 16 hours / day

- Comorbidities such as Parkinson's disease, schizophrenia, renal failure, or any other
severe complication that, in the Investigator's opinion, will compromise the safety of
the patient or confound interpretation of the data collected in this study

- Other neuromuscular disease

- Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's
disease)

- Active infection

- Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)

- Positive HIV or HTLV at Screening

- Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody
to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen
(HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening

- Subjects with known immunosuppression or currently receiving immunosuppressive drugs,
chemotherapy or radiation therapy

- Stroke or myocardial infarction within last 3 months

- Patients with a recent history (< 5 years) of malignant neoplasm except basal cell
carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of
recurrence);

- Subjects requiring > 81 mg daily of acetylsalicylic acid; subjects may be enrolled if
willing/able to switch to = 81 mg daily of acetylsalicylic acid or to another
medication

- Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2
inhibiting drugs, or high dose steroids (excepting inhaled steroids); subjects may be
enrolled if willing/able to undergo medication wash-out prior to the first dosing and
to refrain from taking these drugs for the duration of the study

- Have used an investigational drug within 30 days of Screening

- Pregnant or currently lactating

- Major psychiatric disorder in past 6 months

- Known drug or alcohol dependence or any other factors which will interfere with the
study conduct or interpretation of the results or who in the opinion of the
Investigator are not suitable to participate.



Age minimum: 21 Years
Age maximum: 75 Years
Gender: All
Health Condition(s) or Problem(s) studied
Amyotrophic Lateral Sclerosis
Intervention(s)
Biological: VM202
Primary Outcome(s)
Number of Subjects With Serious and Non Serious Adverse Events [Time Frame: Throughout the nine month follow up]
Secondary Outcome(s)
Change From Baseline (Day 0) in Forced Vital Capacity (%) [Time Frame: Day 30, Day 60, Day 90, at 6 months and 9 months]
The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) [Time Frame: Screening, on Day 0 before the treatment (injection), on Day 30, Day 60, Day 90, at 6 months and 9 months]
Change in Mean Muscle Strength Medical Research Council (MRC) Scores [Time Frame: Day 0, Day 30, Day 60, Day 90, at 6 months and 9 months]
Secondary ID(s)
VMALS-001 / B
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 21/09/2023
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02039401
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history